| Quarter | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
| 16 | 9 | 15 | 10 | 15 | |
Growth YoY Revenue Growth YoY% | -3.4 | 10.8 | -1.0 | ||
| 14 | 6 | 13 | 13 | 12 | |
| 2 | 3 | 2 | -3 | 3 | |
OPM OPM% | 14.2 | 35.1 | 14.5 | -27.9 | 22.3 |
| 1 | 0 | 1 | 5 | 2 | |
Interest Expense Interest ExpenseCr | 0 | 1 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 |
PBT PBTCr | 2 | 3 | 3 | 1 | 5 |
| 1 | 1 | 0 | 1 | 1 | |
| 2 | 2 | 3 | 0 | 3 | |
Growth YoY PAT Growth YoY% | 77.9 | -75.4 | -3.3 | ||
NPM NPM% | 11.9 | 21.5 | 21.9 | 4.8 | 21.4 |
| 3.0 | 3.1 | 9.3 | 1.1 | 3.7 |
| Quarter | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
| 16 | 9 | 15 | 10 | 15 | |
Growth YoY Revenue Growth YoY% | -3.4 | 10.8 | -1.0 | ||
| 14 | 6 | 13 | 13 | 12 | |
| 2 | 3 | 2 | -3 | 3 | |
OPM OPM% | 14.2 | 35.1 | 14.5 | -27.9 | 22.3 |
| 1 | 0 | 1 | 5 | 2 | |
Interest Expense Interest ExpenseCr | 0 | 1 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 |
PBT PBTCr | 2 | 3 | 3 | 1 | 5 |
| 1 | 1 | 0 | 1 | 1 | |
| 2 | 2 | 3 | 0 | 3 | |
Growth YoY PAT Growth YoY% | 77.9 | -75.4 | -3.3 | ||
NPM NPM% | 11.9 | 21.5 | 21.9 | 4.8 | 21.4 |
| 3.0 | 3.1 | 9.3 | 1.1 | 3.7 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
Revenue RevenueCr | 10 | 7 | 16 | 25 | 25 | 25 |
Growth Revenue Growth% | -31.9 | 138.4 | 60.6 | 1.7 | 3.4 | |
| 10 | 5 | 13 | 20 | 26 | 25 | |
| 0 | 2 | 3 | 5 | -1 | 1 | |
OPM OPM% | -3.7 | 23.2 | 16.3 | 21.7 | -2.2 | 2.4 |
| 1 | 1 | 0 | 1 | 6 | 6 | |
Interest Expense Interest ExpenseCr | 0 | 1 | 1 | 1 | 1 | 1 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 1 |
PBT PBTCr | 0 | 1 | 2 | 5 | 5 | 6 |
| 0 | 0 | 0 | 1 | 1 | 2 | |
PAT PATCr | 0 | 1 | 1 | 4 | 4 | 4 |
Growth PAT Growth% | 855.3 | 28.7 | 183.2 | 0.3 | -29.6 | |
NPM NPM% | 1.1 | 16.2 | 8.7 | 15.4 | 15.2 | 14.8 |
| 11.6 | 1.9 | 2.4 | 6.1 | 4.9 | 4.8 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
Revenue RevenueCr | 10 | 7 | 16 | 25 | 25 | 25 |
Growth Revenue Growth% | -31.9 | 138.4 | 60.6 | 1.7 | 3.4 | |
| 10 | 5 | 13 | 20 | 26 | 25 | |
| 0 | 2 | 3 | 5 | -1 | 1 | |
OPM OPM% | -3.7 | 23.2 | 16.3 | 21.7 | -2.2 | 2.4 |
| 1 | 1 | 0 | 1 | 6 | 6 | |
Interest Expense Interest ExpenseCr | 0 | 1 | 1 | 1 | 1 | 1 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 1 |
PBT PBTCr | 0 | 1 | 2 | 5 | 5 | 6 |
| 0 | 0 | 0 | 1 | 1 | 2 | |
PAT PATCr | 0 | 1 | 1 | 4 | 4 | 4 |
Growth PAT Growth% | 855.3 | 28.7 | 183.2 | 0.3 | -29.6 | |
NPM NPM% | 1.1 | 16.2 | 8.7 | 15.4 | 15.2 | 14.8 |
| 11.6 | 1.9 | 2.4 | 6.1 | 4.9 | 4.8 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 1 | 1 | 1 | 6 | 9 | 11 |
Reserves ReservesCr | 0 | 1 | 6 | 5 | 30 | 59 |
| 8 | 10 | 12 | 15 | 9 | ||
| 1 | 2 | 2 | 2 | 4 | ||
| 9 | 14 | 20 | 28 | 52 | 83 | |
| 7 | 11 | 18 | 27 | 41 | ||
| 2 | 3 | 2 | 1 | 11 | ||
| 9 | 14 | 20 | 28 | 52 | 83 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 1 | 1 | 1 | 6 | 9 | 11 |
Reserves ReservesCr | 0 | 1 | 6 | 5 | 30 | 59 |
| 8 | 10 | 12 | 15 | 9 | ||
| 1 | 2 | 2 | 2 | 4 | ||
| 9 | 14 | 20 | 28 | 52 | 83 | |
| 7 | 11 | 18 | 27 | 41 | ||
| 2 | 3 | 2 | 1 | 11 | ||
| 9 | 14 | 20 | 28 | 52 | 83 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| -1 | 0 | -4 | 0 | -10 | |
| 0 | -1 | 0 | 1 | -10 | |
| 1 | 1 | 4 | -1 | 21 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 | 0 | 0 | 1 |
Free Cash Flow Free Cash FlowCr | -1 | -1 | -4 | 1 | -20 |
CFO To PAT CFO To PAT% | -1,072.6 | -29.9 | -291.8 | -0.7 | -263.4 |
CFO To EBITDA CFO To EBITDA% | 333.7 | -20.8 | -155.9 | -0.5 | 1,800.7 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| -1 | 0 | -4 | 0 | -10 | |
| 0 | -1 | 0 | 1 | -10 | |
| 1 | 1 | 4 | -1 | 21 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 | 0 | 0 | 1 |
Free Cash Flow Free Cash FlowCr | -1 | -1 | -4 | 1 | -20 |
CFO To PAT CFO To PAT% | -1,072.6 | -29.9 | -291.8 | -0.7 | -263.4 |
CFO To EBITDA CFO To EBITDA% | 333.7 | -20.8 | -155.9 | -0.5 | 1,800.7 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 62 | 177 | ||||
Price To Earnings Price To Earnings | 16.1 | 33.4 | ||||
Price To Sales Price To Sales | 2.4 | 7.0 | ||||
Price To Book Price To Book | 1.6 | 2.6 | ||||
EV To EBITDA EV To EBITDA | -116.7 | 295.8 | ||||
GPM GPM% | 20.1 | 48.8 | 37.4 | 42.4 | 29.1 | 29.1 |
OPM OPM% | -3.7 | 23.2 | 16.3 | 21.7 | -2.2 | 2.4 |
NPM NPM% | 1.1 | 16.2 | 8.7 | 15.4 | 15.2 | 14.8 |
ROCE ROCE% | 14.0 | 29.5 | 20.8 | 32.6 | 11.9 | 9.0 |
ROE ROE% | 11.9 | 53.2 | 21.3 | 34.9 | 9.9 | 5.4 |
ROA ROA% | 1.2 | 7.7 | 6.7 | 13.7 | 7.5 | 4.5 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 62 | 177 | ||||
Price To Earnings Price To Earnings | 16.1 | 33.4 | ||||
Price To Sales Price To Sales | 2.4 | 7.0 | ||||
Price To Book Price To Book | 1.6 | 2.6 | ||||
EV To EBITDA EV To EBITDA | -116.7 | 295.8 | ||||
GPM GPM% | 20.1 | 48.8 | 37.4 | 42.4 | 29.1 | 29.1 |
OPM OPM% | -3.7 | 23.2 | 16.3 | 21.7 | -2.2 | 2.4 |
NPM NPM% | 1.1 | 16.2 | 8.7 | 15.4 | 15.2 | 14.8 |
ROCE ROCE% | 14.0 | 29.5 | 20.8 | 32.6 | 11.9 | 9.0 |
ROE ROE% | 11.9 | 53.2 | 21.3 | 34.9 | 9.9 | 5.4 |
ROA ROA% | 1.2 | 7.7 | 6.7 | 13.7 | 7.5 | 4.5 |
| Market CapitalizationMkt CapCr | 205 | 202 | 198 | 177 | 154 | 151 | 151 |
| Close PriceClose₹ | 167.10 | 160.70 | 67.20 | 161.70 | 18.54 | 92.00 | 255.24 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 20.60 | 0.28 | 2.72 | 33.41 | 11.24 | 9.47 | 20.13 |
| Price To SalesPS | 2.43 | 3.12 | 2.51 | 6.98 | 0.59 | 1.27 | 0.93 |
| RevenueRevenueCr | 84 | 65 | 79 | 25 | 259 | 118 | 162 |
| Revenue Growth TTMRev Gr TTM% | 22.5% | -14.9% | 3.4% | 50.8% | 7.5% | 24.2% | |
| PAT Growth TTMPAT Gr TTM% | 33.6% | 421.4% | -29.6% | 20.1% | 16.4% | 387.4% |
| Market CapitalizationMkt CapCr | 205 | 202 | 198 | 177 | 154 | 151 | 151 |
| Close PriceClose₹ | 167.10 | 160.70 | 67.20 | 161.70 | 18.54 | 92.00 | 255.24 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 20.60 | 0.28 | 2.72 | 33.41 | 11.24 | 9.47 | 20.13 |
| Price To SalesPS | 2.43 | 3.12 | 2.51 | 6.98 | 0.59 | 1.27 | 0.93 |
| RevenueRevenueCr | 84 | 65 | 79 | 25 | 259 | 118 | 162 |
| Revenue Growth TTMRev Gr TTM% | 22.5% | -14.9% | 3.4% | 50.8% | 7.5% | 24.2% | |
| PAT Growth TTMPAT Gr TTM% | 33.6% | 421.4% | -29.6% | 20.1% | 16.4% | 387.4% |